Global RNA Interference (RNAi)-Based Therapeutics Supply, Demand and Key Producers, 2023-2029

Global RNA Interference (RNAi)-Based Therapeutics Supply, Demand and Key Producers, 2023-2029

The global RNA Interference (RNAi)-Based Therapeutics market size is expected to reach $ 5308.7 million by 2029, rising at a market growth of 26.3% CAGR during the forecast period (2023-2029).

The Small Interfering RNA (siRNA) Drugs Market is driven by the transformative potential of siRNA-based therapies in silencing disease-associated genes, making them a promising approach for treating a wide range of diseases, including genetic disorders, viral infections, and various cancers. siRNA drugs work by selectively degrading or inhibiting the expression of specific genes, offering a highly targeted and personalized treatment option. As the understanding of genomics and RNA interference mechanisms advances, and the need for precision medicine grows, the demand for siRNA drugs continues to rise. Innovations in siRNA design, delivery systems, and gene-editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to overcome delivery barriers, ensure the stability and safety of siRNA therapeutics, and navigate regulatory complexities. Addressing off-target effects, optimizing pharmacokinetics, and managing the high cost of siRNA drug development are ongoing challenges. Additionally, the market faces competition from traditional therapeutic approaches and the need for continuous research and development to unlock the full therapeutic potential of siRNA drugs. Striking a balance between providing safe, effective, and accessible siRNA therapies while addressing scientific and regulatory challenges is essential for the continued growth of the Small Interfering RNA (siRNA) Drugs Market.

This report studies the global RNA Interference (RNAi)-Based Therapeutics demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for RNA Interference (RNAi)-Based Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of RNA Interference (RNAi)-Based Therapeutics that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global RNA Interference (RNAi)-Based Therapeutics total market, 2018-2029, (USD Million)

Global RNA Interference (RNAi)-Based Therapeutics total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: RNA Interference (RNAi)-Based Therapeutics total market, key domestic companies and share, (USD Million)

Global RNA Interference (RNAi)-Based Therapeutics revenue by player and market share 2018-2023, (USD Million)

Global RNA Interference (RNAi)-Based Therapeutics total market by Type, CAGR, 2018-2029, (USD Million)

Global RNA Interference (RNAi)-Based Therapeutics total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global RNA Interference (RNAi)-Based Therapeutics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Alnylam, Novartis, Sylentis, Arrowhead, Silence Therapeutics and Dicerna, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World RNA Interference (RNAi)-Based Therapeutics market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global RNA Interference (RNAi)-Based Therapeutics Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global RNA Interference (RNAi)-Based Therapeutics Market, Segmentation by Type

siRNA

miRNA

shRNA

Global RNA Interference (RNAi)-Based Therapeutics Market, Segmentation by Application

AHP

hATTR

Other

Companies Profiled:

Alnylam

Novartis

Sylentis

Arrowhead

Silence Therapeutics

Dicerna

Key Questions Answered

1. How big is the global RNA Interference (RNAi)-Based Therapeutics market?

2. What is the demand of the global RNA Interference (RNAi)-Based Therapeutics market?

3. What is the year over year growth of the global RNA Interference (RNAi)-Based Therapeutics market?

4. What is the total value of the global RNA Interference (RNAi)-Based Therapeutics market?

5. Who are the major players in the global RNA Interference (RNAi)-Based Therapeutics market?